Published in J Hypertens on June 01, 2001
JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart (2005) 9.79
Bariatric Surgery can Lead to Net Cost Savings to Health Care Systems: Results from a Comprehensive European Decision Analytic Model. Obes Surg (2015) 1.60
Effect of continuous smoking reduction and abstinence on blood pressure and heart rate in smokers switching to electronic cigarettes. Intern Emerg Med (2016) 0.86
Metabolic effects of an AT1-receptor blockade combined with HCTZ in cardiac risk patients: a non interventional study in primary care. BMC Cardiovasc Disord (2008) 0.81
Morning blood pressure at home predicts erythropoietin-induced hypertension in patients with chronic renal diseases. Clin Exp Nephrol (2007) 0.80
Blood Pressure Control in Smokers with Arterial Hypertension Who Switched to Electronic Cigarettes. Int J Environ Res Public Health (2016) 0.79
The kaiser permanente northwest cardiovascular risk factor management program: a model for all. Perm J (2005) 0.75
Effects of individual risk factors on the incidence of cardiovascular event in the treated hypertensive patients of the Hypertension Optimal Treatment Study. J Hypertens (2001) 0.75
Positive Association between Tinnitus and Arterial Hypertension. Front Neurol (2016) 0.75
Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J (2003) 17.80
Molecular analysis of commensal host-microbial relationships in the intestine. Science (2001) 12.04
Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ (1996) 11.60
Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension) Lancet (1991) 9.57
Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA (2001) 8.72
Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens (2004) 8.32
Report of the Canadian Hypertension Society Consensus Conference: 1. Introduction. CMAJ (1993) 6.20
Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J (2005) 5.40
Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomised trial. Lancet (1981) 4.75
Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol (1995) 4.50
Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II) N Engl J Med (1992) 3.87
Coronary heart-disease after treatment of hypertension. Lancet (1978) 3.78
Smoking and myocardial infarction. Lancet (1975) 3.42
Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet (1998) 3.41
Treatment of severe refractory autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab (humanized CD52 monoclonal antibody). Leukemia (2007) 3.33
Recommendations from the Consensus Conference on Hypertension in the Elderly. CMAJ (1986) 3.06
Multivariate analysis of risk factors for coronary heart disease. Circulation (1973) 3.04
Reliability of echocardiographic assessment of left ventricular structure and function: the PRESERVE study. Prospective Randomized Study Evaluating Regression of Ventricular Enlargement. J Am Coll Cardiol (1999) 2.98
Effects of clonidine withdrawal: possible mechanisms and suggestions for management. Br Med J (1973) 2.87
Comparison of Escherichia coli from bacteriuric patients with those from feces of healthy schoolchildren. J Infect Dis (1977) 2.72
1999 World Health Organization-International Society of Hypertension Guidelines for the management of hypertension. Guidelines sub-committee of the World Health Organization. Clin Exp Hypertens (1999) 2.72
Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial. J Hypertens (1987) 2.59
Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Prospective Randomized Open Blinded End-Point. Blood Press (1992) 2.49
Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S) Circulation (1998) 2.40
Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer (2007) 2.36
Cost-effectiveness of cholesterol lowering. Results from the Scandinavian Simvastatin Survival Study (4S) Eur Heart J (1996) 2.31
Hypertension is related to cognitive impairment: a 20-year follow-up of 999 men. Hypertension (1998) 2.31
Cholesterol lowering and the use of healthcare resources. Results of the Scandinavian Simvastatin Survival Study. Circulation (1996) 2.23
Registration of myocardial infarction in the city of Göteborg, Sweden. J Chronic Dis (1975) 2.20
Blood pressure crisis following withdrawal of clonidine (Catapres, Catapresan), with special reference to arterial and urinary catecholamine levels, and suggestions for acute management. Am Heart J (1973) 2.17
Body weight and weight gain during adult life in men in relation to coronary heart disease and mortality. A prospective population study. Eur Heart J (1999) 2.16
Home blood pressure determination. Value in borderline ("labile") hypertension. JAMA (1974) 2.16
Reduction in incidence of diabetes, hypertension and lipid disturbances after intentional weight loss induced by bariatric surgery: the SOS Intervention Study. Obes Res (1999) 2.11
Initial clinical experience with I.C.I. 66.082, a new beta-adrenergic blocking agent, in hypertension. Acta Med Scand (1973) 2.10
The 1993 guidelines for the management of mild hypertension: memorandum from a WHO/ISH meeting. Blood Press (1993) 2.03
Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. J Am Soc Nephrol (2001) 1.94
Practice guidelines for primary care physicians: 2003 ESH/ESC hypertension guidelines. J Hypertens (2003) 1.93
Coordinating and standardizing long-term care: evaluation of the west of Scotland shared-care scheme for hypertension. Br J Gen Pract (1994) 1.92
Cessation of smoking after myocardial infarction. Effects on mortality after 10 years. Br Heart J (1983) 1.90
Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY study. JAMA (1988) 1.87
Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines. Eur J Cancer (2003) 1.86
The multifactor primary prevention trial in Göteborg, Sweden. Eur Heart J (1986) 1.85
Effects of insulin treatment on cause-specific one-year mortality and morbidity in diabetic patients with acute myocardial infarction. DIGAMI Study Group. Diabetes Insulin-Glucose in Acute Myocardial Infarction. Eur Heart J (1996) 1.83
A comparison between participants and non-participants in a primary preventive trial. J Chronic Dis (1976) 1.80
Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group. N Engl J Med (1997) 1.79
Felodipine--a new vasodilator, in addition to beta-receptor blockade in hypertension. Eur J Clin Pharmacol (1983) 1.77
Psychosocial factors and venous thromboembolism: a long-term follow-up study of Swedish men. J Thromb Haemost (2007) 1.74
Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. Am J Hypertens (1992) 1.73
Prognostic value of angiographic indices of coronary artery disease from the Coronary Artery Surgery Study (CASS). J Clin Invest (1983) 1.70
The Hypertension Optimal Treatment (HOT) Study--patient characteristics: randomization, risk profiles, and early blood pressure results. Blood Press (1994) 1.70
Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Arch Intern Med (1996) 1.68
Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial. Kidney Int (2007) 1.67
The reaction of salivary substances with bacteria. J Oral Pathol (1975) 1.66
Is abdominal body fat distribution a major explanation for the sex difference in the incidence of myocardial infarction? The study of men born in 1913 and the study of women, Göteborg, Sweden. Am J Epidemiol (1992) 1.66
Stressful life events, social support, and mortality in men born in 1933. BMJ (1993) 1.66
High prevalence and persistence of sleep apnoea in patients referred for acute left ventricular failure and medically treated over 2 months. Eur Heart J (1999) 1.63
[There is no reason to avoid calcium antagonists in hypertension]. Lakartidningen (1996) 1.62
Coronary heart disease, cancer and mortality in male middle-aged light smokers. J Intern Med (1992) 1.62
Trends in the incidence of chronic Philadelphia chromosome negative (Ph-) myeloproliferative disorders in the city of Göteborg, Sweden, during 1983-99. J Intern Med (2004) 1.62
Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: Main results from the Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS). Circulation (2001) 1.62
AT1-receptor blockers in hypertension and heart failure: clinical experience and future directions. Eur Heart J (1999) 1.61
Efficacy of anticoagulation in the U.K. Lancet (1981) 1.58
Telomere length and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. J Hum Hypertens (2011) 1.56
Peak expiratory flow and risk of cardiovascular disease and death. A 12-year follow-up of participants in the population study of women in Gothenburg, Sweden. Am J Epidemiol (1986) 1.55
Diabetes mellitus and raised serum triglyceride concentration in treated hypertension--are they of prognostic importance? Observational study. BMJ (1996) 1.54
Initial clinical experience with ICI 141,292 (Visacor), a new selective beta 1-adrenoceptor blocker with ISA--a multicentre trial in 59 patients. Br J Clin Pharmacol (1984) 1.53
Coronary heart disease and mortality in middle aged men from different occupational classes in Sweden. BMJ (1988) 1.53
Relation between drug treatment and cancer in hypertensives in the Swedish Trial in Old Patients with Hypertension 2: a 5-year, prospective, randomised, controlled trial. Lancet (2001) 1.52
Patients' attitudes to participation in clinical trials. Br J Clin Pharmacol (1993) 1.52
Lipoprotein (a) and coronary heart disease: a prospective case-control study in a general population sample of middle aged men. BMJ (1990) 1.50
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. Atheroscler Suppl (2004) 1.50
The homogeneity of the faecal coliform flora of normal school-girls, characterized by serological and biochemical properties. Med Microbiol Immunol (1978) 1.49
Secular changes in cardiovascular risk factors and attack rate of myocardial infarction among men aged 50 in Gothenburg, Sweden. Accurate prediction using risk models. J Intern Med (2008) 1.49
Capsaicin-induced cough in humans. Am Rev Respir Dis (1992) 1.49
Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. ASCOT investigators. J Hypertens (2001) 1.49
Influence of gender and age on preventing cardiovascular disease by antihypertensive treatment and acetylsalicylic acid. The HOT study. Hypertension Optimal Treatment. J Hypertens (2000) 1.48
Reversal of cardiovascular structural changes when treating essential hypertension. The importance of the renin-angiotensin-aldosterone system. Am J Hypertens (1992) 1.48
Early disturbances of ambulatory blood pressure load in normotensive type I diabetic patients with microalbuminuria. Diabetes Care (1992) 1.48